A股異動 | 尚榮醫療接近漲停 緬甸醫療防護用品生產基地投產
格隆匯2月24日丨尚榮醫療(002551.SZ)接近漲停,報6.89元,總市值51億元。尚榮醫療旗下普爾德(緬甸)生產基地一期項目於日前正式順利投產。普爾德(緬甸)基地分三期投入,該生產基地的正式投產使用將極大的緩解目前全球市場對公司產品需求激增而導致的國內生產基地的交貨壓力,使得國內生產基地可以抽出更大份額的產能滿足國內狙擊“新冠”病毒疫情一線所需,並同時滿足國家戰略儲備的供貨需求。尚榮旗下普爾德作為全球最具規模的醫用防護服、手術衣、手術包等醫用防護產品的龍頭企業,將助力緩解疫情防控存在的醫療防護用品緊缺問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.